Stifel analysts have maintained a Buy rating and a $28.00 price target for Phathom Pharmaceuticals (NASDAQ:PHAT), focusing on the company's recent developments. Currently trading at $5.59, ...
Global tablet market is now up 9.2%, PC market up just 3.8% The middle of 2024 saw 18% and 11% quarterly increases, Canalys ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback